Adalimumab: Effective TNF-blockade therapy for ankylosing spondylitis

Research output: Contribution to journalReview articlepeer-review


The armamentarium available for the treatment of ankylosing spondylitis (AS) has for decades been inadequate. The recent introduction of tumor necrosis factor (TNF) antagonists for the treatment of AS has proven pivotal and provided patients with AS an effective treatment option. Indeed both infliximab, a human-mouse chimeric monoclonal antibody directed against TNF, and etanercept, a construct of the Fc portion of the human IgG with soluble receptor of TNF, have demonstrated in clinical trials to improve symptoms of pain and stiffness, physical function, quality of life, as well as MRI inflammation. In 2006, another anti-TNF agent, adalimumab, which is a fully human monoclonal antibody, was approved for the treatment of AS. This report reviews the pharmacologic characteristics of adalimumab as well as its efficacy and safety in As.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalFuture Rheumatology
Issue number5
StatePublished - Oct 2007


  • Adalimumab
  • Ankylosing spondylitis
  • Biologic therapy
  • Enthesitis
  • Sacroiliitis
  • TNF antagonists

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Adalimumab: Effective TNF-blockade therapy for ankylosing spondylitis'. Together they form a unique fingerprint.

Cite this